Tuchman tucks in as CMO of Oncolytics
This article was originally published in Scrip
Oncolytics Biotech has appointed Dr Alan Tuchman chief medical officer and senior vice-president of clinical and medical development. Dr Tuchman is currently managing director at MedPro Investors and chair of Neurophysics (where he was previously CEO). He has served on Oncolytics’ scientific advisory board since 2001.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.